Moberg Pharma Extends Distribution Agreement with Menarini Group for Emtrix to Russia

STOCKHOLM, February 9, 2015 -- Moberg Pharma AB (OMX: MOB) today announced that
Berlin-Chemie AG, a member of the Menarini Group – a top 40 global
pharmaceutical company – has been granted the exclusive rights to market and
sell Emtrix® in Russia and Ukraine.
The extended distribution agreement builds on an existing collaboration between
Moberg and Menarini, which resulted in a successful launch of Emtrix® in Italy
and most recently, the expansion to China and Southeast Asia where product
launches have been initiated. The rights to Emtrix® in Russia were released from
a previous distribution agreement with Meda AB. The product was not launched in
Russia under the previous agreement.

Berlin-Chemie/Menarini is a leading regional biopharmaceutical company with full
national coverage in Russia, a sales force with more than 700 sales
representatives and a strong track record of launching and promoting Consumer
Health brands. The global sales of the Menarini Group exceed 3.3 billion Euros.
Russia and Ukraine comprise almost 200 million people and represent a
significant long-term growth opportunity for Moberg Pharma.

“I am very pleased to expand our collaboration with the Menarini Group through
this agreement with Berlin-Chemie – a leading marketer in Eastern Europe. The
Russian market has significant long-term potential for Moberg’s products,” said
Peter Wolpert, CEO of Moberg Pharma AB.

“We look forward to introducing Emtrix® to consumers in Russia. The product has
potential to contribute strongly to our expansion within the Consumer Health
market, as it provides rapid relief for a large segment of patients suffering
from nail fungus”, said Michael Sirotovich, COO at Berlin-Chemie AG’s
International Division.

About this information
Moberg Pharma discloses this information pursuant to the Swedish Securities
Markets Act and/or the Financial Instruments Trading Act. The information was
submitted for publication at 8.30 am (CET) on February 9, 2015.

About Emtrix® and nail disease
Emtrix is a topical treatment used to treat nail disease. Launched in late 2010,
it quickly became the market leader in the Nordics and recently also the best
-selling product in its category in the U.S. The international launch is under
way via a proprietary sales organization in the U.S. and ten partners that hold
rights for 50 markets, including the major EU markets, China, Turkey and Russia.
Emtrix is a prescription-free, over-the-counter product sold under the names
Kerasal Nail®, Naloc™/Nalox™ and Emtrix®. Safety and efficacy have been
demonstrated in several clinical studies including more than 600 patients.
Emtrix has a unique and rapid mechanism of action which brings visible
improvements within 2-4 weeks of treatment. Nail fungus is the most common nail
disease. The condition afflicts approximately 10 percent of the population and
is more common among the elderly. It is generally recognized that there is a
need for new efficacious and safe topical treatments.
For additional information, please contact:
Peter Wolpert, CEO, Phone: +46 (0)70 - 735 71 35, E-mail:
peter.wolpert@mobergpharma.se
Anna Ljung, CFO, Phone: +46 (0)70 – 766 60 30, Email: anna.ljung@mobergpharma.se
About Moberg Pharma
Moberg Pharma AB (MOB.ST) is a rapidly growing Swedish pharmaceutical company
with a direct sales and marketing organization in the U.S. and an extensive
distributor network in more than 40 countries. The company’s OTC portfolio
includes the brands Kerasal®, Jointflex®, Kerasal Nail®, Domeboro®, Vanquish®,
and Fergon®. Kerasal Nail®(Nalox™/ Emtrix®in certain markets outside the U.S.)
is the leading product for the treatment of nail disorders in the U.S. and
Nordic market. The strategy to expand the portfolio includes acquisitions and in
-licensing, as well as internal development with a focus on innovative drug
delivery of proven compounds. Moberg Pharma has offices in Stockholm and New
Jersey and the company’s shares are listed on the Small Cap list of the NASDAQ
OMX Nordic Exchange Stockholm. For further information, please visit:
www.mobergpharma.com.

About Menarini Group
The Menarini Group is the number one Italian pharmaceutical company in the
world, 16th in Europe out of 5,291 companies, and 36th company in the world out
of 19,042 companies, with a turnover of more than 3,3 billion Euro and more than
16,600 employees. The Menarini Group has always pursued two strategic
objectives: Research and Internationalisation and is present in the most
important therapeutic areas including products for cardiology, gastroenterology,
pneumology/antibiotics, diabetology, antinflammatory agents/analgesics. With 14
production sites and 5 Research and Development centres, the Menarini Group has
a strong presence throughout Europe and Asia, Africa, Central and South America.
Menarini’s products are available in more than 100 countries worldwide. For
further information please visit www.menarini.com.